Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Summary

Arcus Biosciences and Summit Therapeutics have entered into a clinical trial collaboration to evaluate the combination of casdatifan and ivonescimab in kidney cancer patients. This partnership represents a strategic combination of two therapeutic agents for oncology indication.